SCHEMBL1390682

SCHEMBL1390682

Fc1ccc(CNc2nc(Cc3ccccc3)nc(OCC(F)(F)F)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
ADORA2A P29274 3/20 0.47
TP53 P04637 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
KCNH3 Q9ULD8 3/20 0.45
GAA P10253 1/20 0.44
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
HTT P42858 1/20 0.43
ATM Q13315 1/20 0.43
USP1 O94782 1/20 0.39
WDR48 Q8TAF3 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1392080 0.86 TP53 (0.49) MAPTADORA2ATP53SMN1; SMN2LMNA
SCHEMBL1391524 0.82 KCNH3 (0.70) MAPTADORA2ATP53LMNAL3MBTL1
SCHEMBL1391347 0.82 MAPT (0.57) MAPTADORA2ATP53SMN1; SMN2LMNA
SCHEMBL1391336 0.80 KCNH3 (0.46) MAPTADORA2ATP53SMN1; SMN2LMNA
SCHEMBL1391352 0.79 MAPT (0.47) MAPTADORA2ATP53SMN1; SMN2LMNA
SCHEMBL1391990 0.76 KCNH3 (0.55) MAPTADORA2ATP53SMN1; SMN2LMNA
SCHEMBL1391240 0.76 LMNA (0.46) MAPTADORA2ATP53SMN1; SMN2LMNA
SCHEMBL1391588 0.75 KCNH3 (0.55) MAPTSMN1; SMN2LMNAL3MBTL1MEN1
SCHEMBL3478810 0.74 MEN1 (0.61) LMNAL3MBTL1MEN1KMT2ATDP1
SCHEMBL1391655 0.74 KDM4E (0.52) MAPTTP53SMN1; SMN2LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 US disclosed
EP-2231624-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF Progenics Pharmaceuticals, Inc. (US) 2010-09-29 EP disclosed
WO-2009091388-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF PROGENICS PHARMACEUTICALS, INC. (US) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS MAPT 3654/4885ADORA2A 2554/4885TP53 1405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.